Kari Magee speaks with Dr Bethany Verkamp to discuss her recent research on evaluating treatment response to etoposide-based treatment in patients with hemophagocytic lymphohistiocytosis (HLH).
Kari Magee speaks with Dr Bethany Verkamp to discuss her recent research on evaluating treatment response to etoposide-based treatment in patients with HLH. Dr Verkamp is a hematology/oncology fellow in the Cancer and Blood Diseases Institute at Cincinnati Children's Hospital. Hear from Dr Verkamp about her research, findings, and important considerations for assessing patient response to first-line etoposide-based HLH therapy.
Follow Us
Presented by Sobi Inc.